Get the Stockscreener App
57.64
0.24%
0.14
After Hours:
57.64
Haemonetics Corp stock is traded at $57.64, with a volume of 1.06M.
It is up +0.24% in the last 24 hours and down -30.49% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$57.50
Open:
$57.53
24h Volume:
1.06M
Relative Volume:
1.14
Market Cap:
$2.68B
Revenue:
$1.35B
Net Income/Loss:
$163.34M
P/E Ratio:
17.59
EPS:
3.2763
Net Cash Flow:
$189.17M
1W Performance:
-11.35%
1M Performance:
-30.49%
6M Performance:
+10.36%
1Y Performance:
-5.99%
1-Day Range:
$55.95
$58.20
1-Week Range:
$55.95
$66.08
52-Week Range:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
57.64 | 2.67B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | Needham | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Haemonetics Releases 2024-2025 Corporate Responsibility Report - TipRanks
5 Revealing Analyst Questions From Haemonetics's Q4 Earnings Call - Finviz
Skylands Capital LLC Has $3.97 Million Stock Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics (HAE) International Revenue Performance Explored - Yahoo Finance
Key Players in the Autotransfusion Systems MarketHaemonetics - openPR.com
Chuck Royce's Strategic Moves: Significant Reduction in Haemonetics Corp - Yahoo Finance
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term - Yahoo Finance
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $75 to $94 - 富途牛牛
Haemonetics Earnings Call: Strong Core, IVT Drag - TipRanks
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI) - The Globe and Mail
Why Haemonetics (HAE) Raised 2026 Guidance After Strong Plasma And Tech Results And What It Signals - Yahoo Finance
Haemonetics (HAE) Margin Strength In Q3 2026 Reinforces Earnings Led Bullish Narratives - simplywall.st
Haemonetics Q3 Earnings Call Highlights - MarketBeat
Haemonetics (NYSE:HAE) Trading Down 5.6%Here's What Happened - MarketBeat
Haemonetics stock slides 7% as revenue dip and hospital softness blunt raised outlook - TechStock²
Citigroup Lowers Price Target for Haemonetics (HAE) to $75 | HAE Stock News - GuruFocus
Mizuho Lowers Haemonetics (HAE) Price Target, Maintains Outperfo - GuruFocus
Haemonetics (HAE) Rating Update: Barrington Research Raises Pric - GuruFocus
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips - Yahoo Finance
Haemonetics' (HAE) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
Haemonetics Corporation (NYSE:HAE) Q3 2026 Earnings Call Transcript - Insider Monkey
Haemonetics price target raised to $94 from $93 at Barrington - TipRanks
Haemonetics (HAE) Valuation Check After Q3 Beat And Higher 2026 Guidance - simplywall.st
HAE Q4 Deep Dive: Plasma Momentum and Hospital Weakness Shape Mixed Results - Finviz
Haemonetics stock maintains Market Outperform rating at Citizens on strong plasma growth - Investing.com Nigeria
Haemonetics stock maintains Market Outperform rating at Citizens on strong plasma growth By Investing.com - Investing.com South Africa
BTIG Reiterates Buy Rating and $88 Price Target on HAE | HAE Sto - GuruFocus
Baird lowers Haemonetics stock price target to $81 on mixed outlook - Investing.com Nigeria
Decoding Haemonetics Corp (HAE): A Strategic SWOT Insight - GuruFocus
Haemonetics Q3 2026 slides: Margin expansion and cash flow surge despite revenue transition - Investing.com Canada
Haemonetics (NYSE:HAE) Announces Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Haemonetics Corp (HAE) Q3 2026 Earnings Call Highlights: Strong - GuruFocus
Haemonetics reports Q3 adjusted EPS $1.31, consensus $1.25 - TipRanks
Haemonetics HAE Q3 2026 Earnings Call Transcript - AOL.com
Haemonetics (HAE) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Haemonetics (HAE) Exceeds Q3 Revenue Expectations with Strong Pe - GuruFocus
Haemonetics's (NYSE:HAE) Q4 CY2025 Sales Top Estimates, Stock Soars - Finviz
Haemonetics (NYSE:HAE) Releases FY 2026 Earnings Guidance - MarketBeat
Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Haemonetics: Fiscal Q3 Earnings Snapshot - kare11.com
Haemonetics beats Q3 expectations, raises fiscal 2026 guidance By Investing.com - Investing.com Nigeria
Haemonetics beats Q3 expectations, raises fiscal 2026 guidance - Investing.com
Haemonetics’s (NYSE:HAE) Q4 CY2025 Sales Top Estimates, Stock Soars - Yahoo Finance
Haemonetics: Fiscal Third Quarter Earnings Overview - Bitget
Haemonetics earnings beat by $0.06, revenue topped estimates - Investing.com
Haemonetics Corporation Q3 Fiscal 2026 Results - TradingView
HAEMONETICS CORP SEC 10-Q Report - TradingView
Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website - PR Newswire
Federated Hermes Inc. Buys 43,042 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Q3 Earnings: Can Momentum Be Sustained? - AD HOC NEWS
What To Expect From Haemonetics's (HAE) Q4 Earnings - Finviz
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):